Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer

pharmafile | September 6, 2019 | News story | Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma 

Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing the regulator’s coveted Breakthrough Therapy designation.

The pharma giant’s drug will now enter review as a first-line treatment of metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a rare mutated form which accounts for 3-4% of lung cancer cases.

The decision means that Novartis will be gearing up to take on Pfizer’s Xalkori, which also secured fast-track designation last year.

“We look forward to working with the FDA and global health authorities to bring capmatinib to patients who currently have no available targeted therapy options,” commented John Tsai, Novartis’s Chief Drug Developer.

Matt Fellows

Related Content

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment

Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its …

Latest content